Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) and Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Institutional & Insider Ownership
52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Whitehawk Therapeutics and Aclaris Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Whitehawk Therapeutics | $7.14 million | 32.82 | -$20.60 million | ($1.12) | -3.67 |
| Aclaris Therapeutics | $7.83 million | 95.00 | -$64.92 million | ($0.58) | -9.17 |
Whitehawk Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings for Whitehawk Therapeutics and Aclaris Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Whitehawk Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| Aclaris Therapeutics | 1 | 0 | 5 | 3 | 3.11 |
Whitehawk Therapeutics currently has a consensus price target of $8.20, suggesting a potential upside of 99.51%. Aclaris Therapeutics has a consensus price target of $11.33, suggesting a potential upside of 113.03%. Given Aclaris Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aclaris Therapeutics is more favorable than Whitehawk Therapeutics.
Profitability
This table compares Whitehawk Therapeutics and Aclaris Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Whitehawk Therapeutics | N/A | -53.89% | -49.97% |
| Aclaris Therapeutics | -921.50% | -61.65% | -42.41% |
Risk & Volatility
Whitehawk Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Summary
Aclaris Therapeutics beats Whitehawk Therapeutics on 8 of the 15 factors compared between the two stocks.
About Whitehawk Therapeutics
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Receive News & Ratings for Whitehawk Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Whitehawk Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
